- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dimitra Diamantopoulou
- Email: dimitra@epetome.com
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89101
- Citruslabs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18-65 years.
- Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
- Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
- Currently on a stable GLP-1 dose as directed by their prescribing physician.
- Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to provide informed consent prior to enrollment.
- In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
- Reside in the United States.
Exclusion Criteria:
- Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
- Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
- Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
- Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
- Anyone currently participating or planning to participate in another research study during the study period.
- Currently receiving immunosuppressant therapy of any kind.
- Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
- Reside in Hawaii.
- Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Synbiotic Dual Cap® Arm
|
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Overall Gastrointestinal Comfort
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bowel Regularity
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bloating
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Constipation
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Diarrhea
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Nausea
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Post-Meal Fullness Comfort
Time Frame: Baseline to Week 12
|
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires |
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Perception of Effect on Overall Gastrointestinal Comfort
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bowel Regularity
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bloating
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Constipation
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Diarrhea
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Nausea
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Post-Meal Fullness Comfort
Time Frame: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Signs and Symptoms, Digestive
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Diabetes Mellitus, Type 2
- Nausea
- Constipation
- Diarrhea
Other Study ID Numbers
- EPETO-21217
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.